Compile Data Set for Download or QSAR
Report error Found 48 Enz. Inhib. hit(s) with all data for entry = 11728
TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642834(US11858905, Compound 34)
Affinity DataIC50: 0.600nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642843(US11858905, Compound 43)
Affinity DataIC50: 0.800nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642846(US11858905, Compound 46)
Affinity DataIC50: 1nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642835(US11858905, Compound 35)
Affinity DataIC50: 1.10nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642829(US11858905, Compound 29)
Affinity DataIC50: 1.30nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642826(US11858905, Compound 26)
Affinity DataIC50: 1.40nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642840(US11858905, Compound 40)
Affinity DataIC50: 1.5nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642839(US11858905, Compound 39)
Affinity DataIC50: 1.60nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642838(US11858905, Compound 38)
Affinity DataIC50: 1.70nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642845(US11858905, Compound 45)
Affinity DataIC50: 2.5nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642833(US11858905, Compound 33)
Affinity DataIC50: 2.90nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642848(US11858905, Compound 48)
Affinity DataIC50: 3.5nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642813(US11858905, Compound 13)
Affinity DataIC50: 3.90nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642820(US11858905, Compound 20)
Affinity DataIC50: 4.20nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642842(US11858905, Compound 42)
Affinity DataIC50: 4.5nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642841(US11858905, Compound 41)
Affinity DataIC50: 5.30nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642822(US11858905, Compound 22)
Affinity DataIC50: 5.30nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642803(US11858905, Compound 3)
Affinity DataIC50: 5.90nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642847(US11858905, Compound 47)
Affinity DataIC50: 6.60nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642806(US11858905, Compound 6)
Affinity DataIC50: 7nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642802(US11858905, Compound 2)
Affinity DataIC50: 7.5nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642821(US11858905, Compound 21)
Affinity DataIC50: 8.20nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642827(US11858905, Compound 27)
Affinity DataIC50: 8.5nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642824(US11858905, Compound 24)
Affinity DataIC50: 9.70nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642831(US11858905, Compound 31)
Affinity DataIC50: 11.7nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642828(US11858905, Compound 28)
Affinity DataIC50: 12.3nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642801(US11858905, Compound 1)
Affinity DataIC50: 14.1nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642844(US11858905, Compound 44)
Affinity DataIC50: 16.5nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642808(US11858905, Compound 8)
Affinity DataIC50: 17.4nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642815(US11858905, Compound 15)
Affinity DataIC50: 19.4nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642807(US11858905, Compound 7)
Affinity DataIC50: 21.1nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642809(US11858905, Compound 9)
Affinity DataIC50: 30.5nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642804(US11858905, Compound 4)
Affinity DataIC50: 34.9nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642825(US11858905, Compound 25)
Affinity DataIC50: 36.7nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642819(US11858905, Compound 19)
Affinity DataIC50: 44.6nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642818(US11858905, Compound 18)
Affinity DataIC50: 50.7nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642810(US11858905, Compound 10)
Affinity DataIC50: 51.5nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642836(US11858905, Compound 36)
Affinity DataIC50: 79.3nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642811(US11858905, Compound 11)
Affinity DataIC50: 94.6nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642805(US11858905, Compound 5)
Affinity DataIC50: 122nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642830(US11858905, Compound 30)
Affinity DataIC50: 124nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642837(US11858905, Compound 37)
Affinity DataIC50: 125nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642816(US11858905, Compound 16)
Affinity DataIC50: 139nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642817(US11858905, Compound 17)
Affinity DataIC50: 201nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642812(US11858905, Compound 12)
Affinity DataIC50: 235nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642823(US11858905, Compound 23)
Affinity DataIC50: 361nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642814(US11858905, Compound 14)
Affinity DataIC50: 534nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent

TargetProcathepsin L(Human)
Biofront Therapeutics (Beijing) Co.

US Patent
LigandPNGBDBM642832(US11858905, Compound 32)
Affinity DataIC50: 1.00E+3nMAssay Description:Human cathepsin L enzymatic assay was performed in assay buffer (50 mM MES pH 5.5, 2.5 mM DTT, 0.5 mM EDTA) to assess the inhibition of human CatL by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2024
Entry Details
Go to US Patent